phrykt

Surgery Partners, Inc. (SGRY): who owns it and who trades it

As of Nov 16, 2026, SGRY insiders reported 12 open-market sales worth $1.3M and 2 purchases worth $305K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason Eric Evans (CEO), with $412K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Surgery Partners

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SGRY

187 funds and institutions reported SGRY shares worth $2.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Bain Capital Investors LLC with 38.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Bain Capital Investors LLC38.2%
Jupiter Topco LLC10.6%
Pentwater Capital Management LP8.9%
UBS Group AG6.6%
BlackRock, Inc.4.8%
King Street Capital Management, L.P.4.6%
T. Rowe Price Investment Management, Inc.4.5%
Dimensional Fund Advisors LP3.8%
Clearbridge Investments, LLC2.9%
Vanguard Portfolio Management LLC2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bain Capital Investors LLC49.95M38.19%$839MNo change
Jupiter Topco LLC13.88M10.61%$233M–
Pentwater Capital Management LP11.63M8.89%$195M-8%
UBS Group AG8.57M6.56%$144M-16%
BlackRock, Inc.6.24M4.77%$105M+10%
King Street Capital Management, L.P.6.06M4.63%$102M-41%
T. Rowe Price Investment Management, Inc.5.92M4.52%$99.4M+203%
Dimensional Fund Advisors LP4.94M3.78%$83.1M-7%
Clearbridge Investments, LLC3.82M2.92%$64.2M-7%
Vanguard Portfolio Management LLC3.74M2.86%$62.8M+3%
Vanguard Capital Management LLC3.51M2.68%$59M+2%
Davidson Kempner Capital Management LP3.34M2.55%$56.1MNo change
HSBC Holdings PLC2.96M2.26%$48.9M+54%
FMR LLC (Fidelity)2.15M1.64%$36.1M-2%
State Street Corp2.14M1.64%$36M+10%
Geode Capital Management, LLC2.12M1.62%$35.6M+6%
Nomura Holdings Inc1.53M1.17%$25.6M+111%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1.47M1.13%$24.7M-7%
LMR Partners LLP1.36M1.04%$22.9M+24%
Morgan Stanley1.23M0.94%$20.7M+22%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SGRY insiders reported $305K of open-market purchases and $1.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$305K
2 trades, 1 people
Sales, 12 months
$1.3M
12 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 18, 2026
Filed Aug 20, 2026

Purchases and sales by month

$1.3M$1.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 18, 2026Teresa DeLucaDirectorPurchase11,250$14.33$161KForm 4
Aug 18, 2026Teresa DeLucaDirectorPurchase10,000$14.35$144KForm 4
Mar 16, 2026David T DohertyCFOSale8,867$12.50$111KForm 4
Mar 16, 2026Jason Eric EvansCEOSale20,400$12.47$254KForm 4
Mar 13, 2026Danielle BurkhalterChief Human Resources OfSale3,469$12.83$44.5KForm 4
Mar 13, 2026Marissa BrittenhamChief Strategy OfficerSale3,657$12.54$45.9KForm 4
Mar 12, 2026Jennifer BaldockChief Admin & Dev OfficeSale5,798$13.17$76.4KForm 4
Mar 6, 2026Jason Eric EvansCEOSale11,462$13.79$158KForm 4
Mar 6, 2026David T DohertyCFOSale14,574$13.84$202KForm 4
Mar 6, 2026Jennifer BaldockChief Admin & Dev OfficeSale10,082$13.70$138KForm 4
Mar 6, 2026Danielle BurkhalterChief Human Resources OfSale7,736$13.60$105KForm 4
Mar 6, 2026William Trenton WebbPresidentSale272$13.93$3.8KForm 4
Mar 6, 2026Marissa BrittenhamChief Strategy OfficerSale8,785$13.70$120KForm 4
Mar 5, 2026William Trenton WebbPresidentSale1,794$13.86$24.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jason Eric EvansChief Executive Officer–$412KMar 16, 2026
David T DohertyChief Financial Officer–$313KMar 16, 2026
Teresa DeLucaDirector$305K–Aug 18, 2026
Jennifer BaldockChief Admin & Dev Officer–$214KMar 12, 2026
Marissa BrittenhamChief Strategy Officer–$166KMar 13, 2026
Danielle BurkhalterChief Human Resources Officer–$150KMar 13, 2026
William Trenton WebbAmerican Group President–$28.7KMar 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SGRY short interest

Moderate short interest. 6.8% of SGRY shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went down 38%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.95M SGRY shares were sold short, 6.8% of the shares outstanding, down 37.5% from the report before. At the average daily volume of 8.51M shares, buying them all back would take about 1.1 trading days (days to cover).

Shares short, % of all shares

6.84%May 15Oct 3012.3%

Days to cover

1.1May 15Oct 3013.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.95M6.84%-38%8.51M1.1
Oct 15, 202614.33M10.95%-0%1.39M10.3
Sep 30, 202614.35M10.96%+8%2.68M5.3
Sep 15, 202613.29M10.15%+3%2.09M6.4
Aug 31, 202612.95M9.90%+2%2.77M4.7
Aug 14, 202612.65M9.66%-7%2.10M6.0
Jul 31, 202613.54M10.35%-9%1.52M8.9
Jul 15, 202614.80M11.32%-2%1.30M11.4
Jun 30, 202615.13M11.56%+6%1.45M10.4
Jun 15, 202614.27M10.91%+4%1.33M10.8
May 29, 202613.72M10.49%-5%1.18M11.6
May 15, 202614.49M11.08%-8%2.21M6.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Surgery Partners company events

Surgery Partners filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Nov 9, 2026AgreementSurgery Partners, Inc., a Delaware corporation, entered into Amendment No. 1 to Agreement and Plan of Merger with Spyglass Topco, LLC, a Delaware limited liability company, Spyglass Merger Subsidiary, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent, and, solely for the limited… Filing
  3. Oct 26, 2026AgreementSurgery Partners, Inc. entered into an Agreement and Plan of Merger with Spyglass Topco, LLC, a Delaware limited liability company, Spyglass Merger Subsidiary, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent, and, solely for the limited purposes set forth therein, Bon Secours… Filing
  4. Sep 17, 2026DealSurgery Partners, Inc., through certain of its subsi diaries, completed the disposition of Moun tain View Hospital, LLC and Idaho Falls Community Hospital, LLC, to Intermountain Health. Filing
  5. Aug 10, 2026ResultsReleased financial results. Filing
  6. Jul 24, 2026AgreementA subsidiary of Surgery Partners, Inc., the Company and Intermountain Health placed into escrow pursuant to a binding agreement their respective signature pages to two Securities Purchase Agreements, pursuant to which Buyer would agree to acquire from Seller its ownership interests in Mountain View… Filing
  7. Jun 5, 2026VoteReported shareholder vote results. Filing
  8. May 5, 2026ResultsReleased financial results. Filing
  9. Mar 2, 2026ResultsReleased financial results. Filing
  10. Dec 16, 2025AgreementSurgery Center Holdings, Inc., a wholly-owned subsidiary of Surgery Partners, Inc., issued an additional $425.0 million of 7.250% Senior Notes due 2032. Filing
  11. Dec 12, 2025AnnouncementSurgery Center Holdings, Inc., entered into a purchase agreement with Barclays Capital Inc. as representative of certain initial purchasers, relating to the issuance and sale of $425.0 million in of the Issuer’s 7.250% senior unsecured notes due 2032. Filing
  12. Dec 11, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Surgery Partners financials

Famous investors that hold SGRY

4 of the 50 well-known investors we track reported holding SGRY in their latest 13F filing. The largest position is Larry Robbins's, worth $90.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Larry Robbins · Glenview Capital ManagementQ3 20266.52M$90.4M1.6%New
Howard Marks · Oaktree Capital ManagementQ2 2026862,588$14.5M0.4%New
Ken Griffin · Citadel AdvisorsQ3 2026550,377$7.6M0.0%+89%
Paul Tudor Jones · Tudor Investment CorpQ3 2026273,208$3.8M0.0%+77%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named SGRY in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Pentwater Capital Management LP13G/A8.3%
Nov 16, 2026Pentwater Capital Management LP13G/A8.3%
Nov 6, 2026JANUS HENDERSON GROUP Ltd.13G/A4.9%
Nov 6, 2026JANUS HENDERSON GROUP Ltd.13G/A4.9%
Oct 26, 2026BCPE Seminole Holdings LP13D/A8.2%
Oct 26, 2026BCPE Seminole Holdings LP13D/A8.2%
Oct 13, 2026GLENVIEW CAPITAL MANAGEMENT, LLC13G5.4%
Oct 13, 2026GLENVIEW CAPITAL MANAGEMENT, LLC13G5.4%

Questions about Surgery Partners, Inc. (SGRY) stock

Who owns the most SGRY stock?

The largest reported owner of Surgery Partners, Inc. (SGRY) is Bain Capital Investors LLC, with 38.2% of the company. In total, 187 funds and institutions reported holding SGRY at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SGRY insiders buying or selling?

In the last 12 months, SGRY insiders reported 2 open-market purchases worth $305K and 12 sales worth $1.3M. The latest trade was on Aug 18, 2026. See every trade.

What is the short interest in SGRY?

As of Oct 30, 2026, 8.95M SGRY shares were sold short, 6.8% of the shares outstanding, down 37.5% from the report before. At the average daily volume of 8.51M shares, buying them all back would take about 1.1 trading days (days to cover). See the history.

Which famous investors hold SGRY?

4 of the 50 well-known investors we track reported SGRY in their latest 13F filing, including Larry Robbins, Howard Marks, Ken Griffin. The largest position is worth $90.4M. See all holders.

Executive pay

Surgery Partners's chief executive was paid a total of $6.1M for the year ended Dec 31, 2025, down 6% from $6.5M the year before. In the last 12 months, Surgery Partners's executives and directors bought $305K of stock on the open market and sold $1.3M.

Chief executive, total pay$6.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.